Form 4: Bausch Health Director Amy Wechsler Receives Equity Compensation

Bausch Health Companies Inc. Director Amy B. Wechsler acquired 1,032 common shares as Restricted Share Units in lieu of cash compensation for her board service.

Summary

• Amy B. Wechsler, a Director of Bausch Health Companies Inc. (BHC), acquired 1,032 common shares.
• The acquisition occurred on June 30, 2025, and was reported on July 2, 2025.
• These shares were issued as Restricted Share Units (RSUs) in lieu of cash compensation for her service on the Board of Directors for the quarter ending June 30, 2025.
• The transaction price for these shares was $0, consistent with equity compensation.
• Following this transaction, Amy B. Wechsler beneficially owns a total of 264,387 common shares of Bausch Health Companies Inc.

Sentiment

Score: 7

Explanation: The transaction reflects routine equity compensation for a director, which aligns management interests with shareholders, generally viewed as a positive corporate governance practice.

Positives

• The issuance of Restricted Share Units (RSUs) to a director aligns their interests with those of shareholders, as the value of their compensation is directly tied to the company's stock performance.
• Utilizing equity compensation in lieu of cash can help conserve the company's cash reserves, which can be beneficial for liquidity and operational funding.

Negatives

• No specific negative financial or operational information is disclosed in this Form 4 filing.

Risks

• This Form 4 filing does not contain information regarding specific company risks.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• Restricted Share Units were issued in lieu of cash compensation in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ending June 30, 2025.

Industry Context

The practice of compensating directors with equity, such as Restricted Share Units, is a common corporate governance practice across various industries, including pharmaceuticals and healthcare, to align director incentives with shareholder value creation.

Comparison to Industry Standards

• Compensating directors with equity, specifically Restricted Share Units (RSUs), is a widely accepted practice in corporate governance across industries, including the pharmaceutical and healthcare sectors where Bausch Health operates.
• This method is comparable to practices at companies like Pfizer, Johnson & Johnson, and Merck, which also utilize equity-based compensation to align the interests of their board members with long-term shareholder value.
• The specific amount of RSUs granted would typically be benchmarked against peer group compensation data, though this filing does not provide such comparative figures.

Management Changes

Corporate Governance

Legal Proceedings

• No legal proceedings or regulatory matters are disclosed in this Form 4 filing.

Related Party Transactions

• The acquisition of shares by a director as compensation for board service constitutes a related party transaction, which is a standard and disclosed practice for executive and director remuneration.

Stakeholder Impact

• Shareholders may benefit from increased alignment of director interests with long-term company performance due to equity-based compensation.

Next Steps

• No specific future actions or milestones are detailed in this Form 4 filing.

Key Dates

Recommendation

Keywords

Bausch Health, BHC, Form 4, insider transaction, director compensation, equity compensation, RSU, restricted share units, corporate governance